Evidence map›Paper›PMID 27848933›Full record

ArticleNature communications2016

Genome editing in maize directed by CRISPR-Cas9 ribonucleoprotein complexes.

Sergei Svitashev, Christine Schwartz, Brian Lenderts, Joshua K Young, A Mark Cigan

Abstract read
In one paragraph

Article in Nature communications, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 337 papers.

0numbers the graph read from it
0cells of the map it votes in
337citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

337 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Genome Editing Approaches in Flax (International journal of molecular sciences · 2026
    Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Genetic transformation and genome editing of flax (Frontiers in plant science · 2026
    Review
  13. Review
  14. Review
  15. Review
  16. Development ofFrontiers in genome editing · 2026
    Article
  17. Article
  18. Review
  19. Article
  20. Article

277 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Sergei SvitashevTrait Enabling Technologies, DuPont Pioneer, Johnston, Iowa 50131, USA.
Christine SchwartzTrait Enabling Technologies, DuPont Pioneer, Johnston, Iowa 50131, USA.
Brian LendertsTrait Enabling Technologies, DuPont Pioneer, Johnston, Iowa 50131, USA.
Joshua K YoungTrait Enabling Technologies, DuPont Pioneer, Johnston, Iowa 50131, USA.
A Mark CiganTrait Enabling Technologies, DuPont Pioneer, Johnston, Iowa 50131, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Targeted DNA double-strand breaks have been shown to significantly increase the frequency and precision of genome editing. In the past two decades, several double-strand break technologies have been developed. CRISPR-Cas9 has quickly become the technology of choice for genome editing due to its simplicity, efficiency and versatility. Currently, genome editing in plants primarily relies on delivering double-strand break reagents in the form of DNA vectors. Here we report biolistic delivery of pre-assembled Cas9-gRNA ribonucleoproteins into maize embryo cells and regeneration of plants with both mutated and edited alleles. Using this method of delivery, we also demonstrate DNA- and selectable marker-free gene mutagenesis in maize and recovery of plants with mutated alleles at high frequencies. These results open new opportunities to accelerate breeding practices in a wide variety of crop species.

Indexed as

Gene EditingAllelesBase SequenceBiolisticsCRISPR-Cas SystemsDNA, PlantGenes, PlantGene Transfer TechniquesMultiprotein ComplexesMutagenesisMutationMutation RateRibonucleoproteinsRNA, Guide, CRISPR-Cas SystemsZea maysDNA, PlantMultiprotein ComplexesRibonucleoproteinsRNA, Guide, CRISPR-Cas Systems

Identifiers

PMID27848933
PMCPMC5116081

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.